Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2019

View Archived Issues

Failure of AMPK caused by multiple uremic factors is a key mechanism of energy depletion in CKD

Localized cell death processes contribute to neurodegeneration

Epigenetic protein switches function after development

New HPV vaccine overcomes viral-type specificity

PIN Pharma presents first-in-human study results for its precision immune stimulant PIN-2

Medivir patents new MALT1 inhibitors

Preliminary data announced from phase I study of HPN-424 in patients with prostate cancer

Eloxx Pharmaceuticals synthesizes compounds for genetic disorders

Results presented from phase III CASSINI study evaluating rivaroxaban thromboprophylaxis

Institute of Materia Medica of Beijing presents compounds for cough

Deciphera Pharmaceuticals reports preliminary data from its ongoing phase I study of DCC-3014

Merck & Co. discloses muscarinic M4 receptor PAMs

Boehringer Ingelheim patents VNN1 inhibitors

FDA approves Sprycel with chemotherapy for pediatric Ph+ ALL

Propanc Biopharma enters collaboration with University of Jaen

Phase II trial of AEVI-001 in pediatric ADHD does not meet primary endpoint

Adlai and Merck & Co. enter clinical trial collaboration to study AN-0025 with Keytruda

Chinese NMPA accepts IND for Asceltis Pharma's third HCV drug ASC-21

Flexion initiates phase III study of Zilretta for hip osteoarthritis

TIM-3/Gal-9 autocrine signaling loop unveiled as therapeutic target for AML

FDA accepts IND for phase Ib study of DM-199 for diabetes-related CKD

U.S. patients to join global phase II trial of mavrilimumab for giant cell arteritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...